You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameButabarbital
Accession NumberDB00237  (APRD00752)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionButabarbital (trade name Butisol) is a prescription barbiturate sleep aid. Butabarbital has a particularly fast onset of effects and short duration of action compared to other barbiturates, which makes it useful for certain applications such as treating severe insomnia and relieving anxiety before surgical procedures; however it is also relatively dangerous particularly when combined with alcohol, and so is now rarely used, although it is still prescribed in some Eastern European and South American countries. Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital. [Wikipedia]
Structure
Thumb
Synonyms
5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-(1-methylpropyl)barbituric acid
5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Sec-butyl-5-ethylbarbituric acid
5-Sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
Butabarbital
Butisol
Secbutabarbital
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butisol SodiumTablet30 mg/1OralMeda Pharmaceuticals Inc.1939-08-01Not applicableUs
Butisol Sodium Tab 100mgTablet100 mgOralCarter Horner Corp.1982-12-312001-01-02Canada
Butisol Sodium Tab 15mgTablet15 mgOralCarter Horner Corp.1982-12-312001-01-02Canada
Butisol Sodium Tab 30mgTablet30 mgOralCarter Horner Corp.1982-12-312001-01-02Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ButalanNot Available
ButisolNot Available
Sarisol No. 2Not Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Butabarbital Sodium
Thumb
  • InChI Key: QORQZMBCPRBCAB-UHFFFAOYNA-M
  • Monoisotopic Mass: 234.098037031
  • Average Mass: 234.2275
DBSALT000312
Categories
UNIIP0078O25A9
CAS number125-40-6
WeightAverage: 212.2456
Monoisotopic: 212.116092388
Chemical FormulaC10H16N2O3
InChI KeyZRIHAIZYIMGOAB-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
IUPAC Name
5-(butan-2-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
SMILES
CCC(C)C1(CC)C(=O)NC(=O)NC1=O
Pharmacology
IndicationFor short-term treatment of insomnia and anxiety disorders
Structured Indications
PharmacodynamicsButabarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionButabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
TargetKindPharmacological actionActionsOrganismUniProt ID
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Neuronal acetylcholine receptor subunit alpha-4Proteinunknown
antagonist
HumanP43681 details
Neuronal acetylcholine receptor subunit alpha-7Proteinunknown
antagonist
HumanP36544 details
Glutamate receptor 2Proteinunknown
antagonist
HumanP42262 details
Glutamate receptor ionotropic, kainate 2Proteinunknown
antagonist
HumanQ13002 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and most metabolic products are excreted in the urine.
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Butabarbital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Butabarbital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alprazolam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Azaperone.Vet Approved
AzelastineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Bupivacaine.Approved, Investigational
BuprenorphineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone.Approved, Investigational
ButacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Codeine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Butabarbital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Butabarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Butabarbital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butabarbital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Eszopiclone.Approved
EthanolButabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butabarbital.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butabarbital.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Butabarbital is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hexobarbital.Approved
HydrocodoneButabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butabarbital.Approved
LoxapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Butabarbital is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Butabarbital is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methohexital.Approved
MethotrimeprazineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methylphenobarbital.Approved
MetyrosineButabarbital may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Butabarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Investigational
MirtazapineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Butabarbital is combined with Opium.Approved, Illicit
OrphenadrineButabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone.Approved
ParaldehydeButabarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pethidine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.Approved
PramipexoleButabarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butabarbital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Butabarbital is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butabarbital.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Romifidine.Vet Approved
RopiniroleButabarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine.Approved
RotigotineButabarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butabarbital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Butabarbital is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Butabarbital is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved
StiripentolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride.Approved
SuvorexantButabarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butabarbital.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrodotoxin.Investigational
ThalidomideButabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Butabarbital is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Butabarbital is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Butabarbital is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zolazepam.Vet Approved
ZolpidemButabarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9324
Blood Brain Barrier+0.9782
Caco-2 permeable-0.6013
P-glycoprotein substrateSubstrate0.5938
P-glycoprotein inhibitor INon-inhibitor0.617
P-glycoprotein inhibitor IINon-inhibitor0.961
Renal organic cation transporterNon-inhibitor0.9465
CYP450 2C9 substrateNon-substrate0.7719
CYP450 2D6 substrateNon-substrate0.9014
CYP450 3A4 substrateNon-substrate0.7098
CYP450 1A2 substrateNon-inhibitor0.8775
CYP450 2C9 inhibitorNon-inhibitor0.821
CYP450 2D6 inhibitorNon-inhibitor0.933
CYP450 2C19 inhibitorNon-inhibitor0.7828
CYP450 3A4 inhibitorNon-inhibitor0.9203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9458
Ames testNon AMES toxic0.6458
CarcinogenicityNon-carcinogens0.8533
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity3.6803 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.9233
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Alpharma us pharmaceuticals division
  • Wockhardt eu operations (swiss) ag
  • Lannett co inc
  • Meda pharmaceuticals inc
  • Halsey drug co inc
  • Cm bundy co
  • Sandoz inc
  • Solvay pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Whiteworth towne paulsen inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Marshall pharmacal corp
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
TabletOral30 mg/1
TabletOral100 mg
TabletOral15 mg
TabletOral30 mg
Prices
Unit descriptionCostUnit
Butisol sodium 50 mg tablet2.46USD tablet
Butisol sodium 30 mg tablet1.89USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point166.5 °CPhysProp
water solubility1360 mg/LNot Available
logP1.65WONG,O & MCKEOWN,RH (1988)
Predicted Properties
PropertyValueSource
Water Solubility1.39 mg/mLALOGPS
logP1.7ALOGPS
logP1.45ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.4 m3·mol-1ChemAxon
Polarizability21.41 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-6900000000-6e0cbc3d26c5541ad8ebView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23